Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Lilly Plans To File Arxxant NDA On Strength Of Single Phase III Trial

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The company will pursue a diabetic nephropathy indication for the protein kinase C-beta inhibitor following initial submission for diabetic retinopathy.

You may also be interested in...



Lilly’s Arxxant Granted Priority Review For Diabetic Retinopathy

Phase III trials are ongoing for additional indications for the protein kinase C-beta inhibitor ruboxistaurin.

Lilly’s Arxxant Granted Priority Review For Diabetic Retinopathy

Phase III trials are ongoing for additional indications for the protein kinase C-beta inhibitor ruboxistaurin.

Lilly Focuses On Ruboxistaurin Retinopathy NDA After Failed Neuropathy Trials

Two trials of reboxistaurin (proposed trade name Arxxant) in diabetic peripheral neuropathy fail to demonstrate statistically significant differences in sensory symptom scores.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS061496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By